Israelsen SB, Ernst MT, Lundh A, et al. - A nationwide study and meta-analysis were conducted to explore whether proton pump inhibitor use is not strongly correlated with SARS-CoV-2 related outcomes. A nationwide observational study was performed including all SARS-CoV-2 cases (n=83,224) in Denmark as of December 1, 2020. Researchers analyzed the relationship between current proton pump inhibitor (PPI) use and the risk of infection in a case-control design. They evaluated the risk of severe outcomes, including mechanical ventilation, ICU admission, or death, in current PPI users (n=4,473) compared to never users. The results demonstrate that current PPI use may be correlated with an elevated risk of SARS-CoV-2 infection and hospital admission, but these results with minimally increased estimates are most likely subject to residual confounding. There was no relationship between severe outcomes. The outcomes from the meta-analysis demonstrated no impact of current PPI use on COVID-19 outcomes.